Tivozanib multi target TKI

Renal-cell carcinoma (advanced)

All type of patients:  1 trials  - TIVO-1

tivozanib vs sorafenib

No demonstrated result

suggested progression or death (progression free survival PFS) by 20% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons